Log in | Register

Statins in patients with sepsis and ARDS: is it over? No

Peter S. Kruger| Marius Terblanche
Editorial
Volume 43, Issue 5 / May , 2017

Pages 675 - 676

No abstract available.

References

  1. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:1308–1316
    • View reference on publisher's website
    • View reference on PubMed
  2. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ (2014) Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 42:625–631
    • View reference on publisher's website
    • View reference on PubMed
  3. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851
    • View reference on publisher's website
    • View reference on PubMed
  4. Wenzel RP, Edmond MB (2012) Septic shock—evaluating another failed treatment. N Engl J Med 366:2122–2124
    • View reference on publisher's website
    • View reference on PubMed
  5. Kruger PS, Venkatesh B (2014) Are there any benefits from statin treatment for the septic patient? Curr Atheroscler Rep 16:378
    • View reference on publisher's website
    • View reference on PubMed
  6. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG (2007) Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 7:358–368
    • View reference on publisher's website
    • View reference on PubMed
  7. Wan YD, Sun TW, Kan QC, Guan FX, Zhang SG (2014) Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit Care 18:R71
    • View reference on publisher's website
    • View reference on PubMed
  8. Thomas G, Hraiech S, Loundou A, Truwit J, Kruger P, McAuley DF, Papazian L, Roch A (2015) Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Miner Anestesiol 81:921–930
  9. Depuydt PO, Kress JP, Salluh JI (2016) The ten “diseases” that are not true diseases. Intensive Care Med 42:411–414
  10. Twaddell S (2009) Surrogate outcome markers in research and clinical practice. Aus Prescr 32:47–50
    • View reference on publisher's website
  11. Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G (2016) The fragility index in multicenter randomized controlled critical care trials. Crit Care Med 44:1278–1284
    • View reference on publisher's website
    • View reference on PubMed
  12. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, McNally C (2014) Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371:1695–1703
    • View reference on publisher's website
    • View reference on PubMed
  13. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts MS, Syres G, Venkatesh B (2013) A multicentre randomised trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 187:743–750
    • View reference on publisher's website
    • View reference on PubMed
  14. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, Barnett AH, Jones A, Hong T, Cooke MW, Perkins GD, Gao F (2012) Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS trial). Crit Care 16:R231
    • View reference on publisher's website
    • View reference on PubMed
  15. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B (2011) Continuation of statin therapy in patients with presumed infection: a randomised controlled trial. Am J Respir Crit Care Med 183:774–781
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement